![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TMEM56 |
Gene summary for TMEM56 |
![]() |
Gene information | Species | Human | Gene symbol | TMEM56 | Gene ID | 148534 |
Gene name | TLC domain containing 4 | |
Gene Alias | TMEM56 | |
Cytomap | 1p21.3 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q96MV1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
148534 | TMEM56 | S43 | Human | Liver | Cirrhotic | 9.14e-03 | -1.54e-01 | -0.0187 |
148534 | TMEM56 | HCC1_Meng | Human | Liver | HCC | 7.97e-68 | 2.32e-02 | 0.0246 |
148534 | TMEM56 | HCC2_Meng | Human | Liver | HCC | 1.04e-07 | -7.82e-02 | 0.0107 |
148534 | TMEM56 | HCC1 | Human | Liver | HCC | 8.84e-14 | 2.68e+00 | 0.5336 |
148534 | TMEM56 | HCC2 | Human | Liver | HCC | 4.73e-27 | 3.34e+00 | 0.5341 |
148534 | TMEM56 | HCC5 | Human | Liver | HCC | 3.82e-13 | 2.12e+00 | 0.4932 |
148534 | TMEM56 | Pt14.b | Human | Liver | HCC | 3.43e-02 | 1.82e-01 | 0.018 |
148534 | TMEM56 | S014 | Human | Liver | HCC | 1.84e-05 | 4.73e-01 | 0.2254 |
148534 | TMEM56 | S015 | Human | Liver | HCC | 7.97e-15 | 8.67e-01 | 0.2375 |
148534 | TMEM56 | S016 | Human | Liver | HCC | 5.89e-06 | 5.41e-01 | 0.2243 |
148534 | TMEM56 | S028 | Human | Liver | HCC | 1.68e-05 | 4.53e-01 | 0.2503 |
148534 | TMEM56 | S029 | Human | Liver | HCC | 1.22e-06 | 5.87e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM56 | SNV | Missense_Mutation | novel | c.116N>T | p.Asn39Ile | p.N39I | Q96MV1 | protein_coding | tolerated(0.1) | benign(0.031) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM56 | insertion | Frame_Shift_Ins | novel | c.400-1_400insA | p.Asn135LysfsTer28 | p.N135Kfs*28 | Q96MV1 | protein_coding | TCGA-AP-A05O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | ||
TMEM56 | SNV | Missense_Mutation | c.69N>G | p.Phe23Leu | p.F23L | Q96MV1 | protein_coding | deleterious(0) | possibly_damaging(0.863) | TCGA-DD-AADR-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
TMEM56 | deletion | Frame_Shift_Del | novel | c.9delC | p.Asn4ThrfsTer23 | p.N4Tfs*23 | Q96MV1 | protein_coding | TCGA-DD-AACD-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | ||
TMEM56 | SNV | Missense_Mutation | novel | c.187N>T | p.Gly63Cys | p.G63C | Q96MV1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD |
TMEM56 | SNV | Missense_Mutation | c.216C>A | p.Phe72Leu | p.F72L | Q96MV1 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-55-7724-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMEM56 | SNV | Missense_Mutation | c.229N>G | p.Lys77Glu | p.K77E | Q96MV1 | protein_coding | tolerated(1) | benign(0.124) | TCGA-78-7220-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
TMEM56 | SNV | Missense_Mutation | rs774641830 | c.433N>T | p.Arg145Cys | p.R145C | Q96MV1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-91-A4BC-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TMEM56 | SNV | Missense_Mutation | novel | c.739C>G | p.His247Asp | p.H247D | Q96MV1 | protein_coding | tolerated(0.18) | benign(0) | TCGA-56-8626-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TMEM56 | SNV | Missense_Mutation | novel | c.210C>G | p.Phe70Leu | p.F70L | Q96MV1 | protein_coding | tolerated(1) | benign(0) | TCGA-98-8021-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |